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DOI 10.1016/j.stem.2009.02.011Weappreciate the support fromboth sets of
authors (Daley et al., 2009; Ellis et al., 2009)
in our efforts to propose guidelines for the
generation and characterization of iPSCs
and for raising additional valuable points
that increase the breadth of our review.
Amajor goal of our Protocol Reviewwas
to propose a common set of criteria for the
characterization of iPSCs in an emerging
field, through direct comparison with our
knowledge of ESCs, which represent the
best characterized pluripotent cell type.
We acknowledge the existence and
value of other pluripotent cell populations,
such as EpiSCs and FAB-SCs, that do not
fulfill all criteria of pluripotency such as
germline transmission. If it is possible to
derive pluripotent cell lines akin to EpiSCs
and FAB-SCs directly from somatic cells,
it may be helpful to introduce new nomen-
clature to distinguish them from conven-
tional iPSCs. This will also necessitate
a dynamic development and continuous
reflection of the criteria used to define
iPSCs aswell as other induced pluripotent
cell populations.202 Cell Stem Cell 4, March 6, 2009 ª2009 EWe agree with Ellis et al. that the use of
in vitro assays to assess the differentiation
capacity of iPSCs is a powerful approach
for the development of directed differenti-
ation protocols; for example, cell-type-
specific tests such as transplantation
can provide more detailed information on
functional differentiation capacity than
that offered by teratoma formation.
However, since in vitro assays are often
more difficult to perform and standardize,
we concur with Daley et al. that a common
assay such as teratoma formation is still
warranted, particularly when the intention
is to simply verify pluripotency of iPSCs.
The availability of reporter constructs is
certain to advance progress in the field,
and their use in the experimental applica-
tions mentioned by Ellis and coauthors
should be encouraged. We would like to
reaffirm, however, that the use of trans-
genic reporters as surrogate markers
for reprogrammed cells should be ap-
proachedwith caution, so as not to equate
reporter-expressing cells with genuine
iPSCs which can misguide interpretationlsevier Inc.of optimization procedures for iPSC deri-
vation.
In conclusion, we thank both groups of
authors for their constructive comments
on our Protocol Review and welcome
further discussion of the criteria for iPSC
characterization as the field advances
and our knowledge of pluripotent cell pop-
ulations increases. In order to bring
consistency to the field and enable cross-
lab comparisons of iPSC derivation proto-
cols, we encourage our colleagues with
extensive experience in deriving pluripo-
tent cells to convene a taskforce to collab-
oratively develop consensus standards by
which the field may assess existing and
future lines.
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